Background
==========

cGMP-dependent protein kinase (PKG) is a serine/threonine kinase which is potently activated by cGMP \[[@B1]\]. PKG is encoded by two genes, forming two different proteins, PKGI and PKGII. The two isoforms of PKGI, PKGIα and PKGIβ, differ in the N-terminal amino acid sequences. PKGI isozymes are homodimers with two identical subunits possessing a catalytic and a regulatory domain each. The regulatory domain contains two non-identical binding sites for cyclic nucleotides (cNMPs), i.e., a slowly exchanging and a rapidly exchanging site. The activation constant (K~a~) of PKGIα for cGMP is about 3-fold lower than the corresponding K~a~ of PKGIβ suggesting distinct physiological roles of the isoforms. In addition to cGMP, other cNMPs and also cNMP analogues activate or inhibit PKG \[[@B2]-[@B4]\]. While many investigations focussed on discrimination between the cNMP binding sites by employing cGMP and cAMP analogues, little is known about interaction of PKGIα with cCMP analogues or with *Rp*- and *Sp*- diastereomers of cCMP phosphorothioates.

As was shown by Desch et al. \[[@B5]\], the membrane-permeable cCMP analogue dibutyryl-cCMP (DB-cCMP) induces smooth muscle relaxation and activates PKGI in aortic tissue lysates. Therefore, we have studied 4-MB-cCMP, the resulting active metabolite after cleavage of DB-cCMP by esterases, and also corresponding substances from cAMP and cGMP, on purified PKGIα.

Materials and methods
=====================

PKG kinase activity was measured *in-vitro* by a radiometric kinase assay in the presence of cGMP or different cNMP analogues. pEC~50~ values, K~a~, Hill slopes and E~max~ values were calculated using GraphPad Prism software. E~max~ values were related to E~max~ values of the activation of PKGIα by cGMP, which was set to 1.00.

Results and discussion
======================

Besides the known activator cGMP, many other cNMPs and cNMP analogues are activators of PKGIα, with distinct activation constants (pEC~50~), specific Hill slopes and different maximal effects (E~max~) (Table [1](#T1){ref-type="table"}). The most potent and effective activator for PKGIα was cGMP. The active metabolite of DB-cGMP, 2-MB-cGMP was less potent and effective.

###### 

pEC~50~, K~a~, Hill slopes and E~max~ for the activation of PKGIα by cNMPs.

  cNMP            pEC~50~           K~a~ (µM)   Hill slope        E~max~
  --------------- ----------------- ----------- ----------------- -----------------
  cGMP\*\*        6.98 ± 0.04       0.11        1.71 ± 0.36       1.00 ± 0.04
                                                                  
  2-MB-cGMP       5.84 ± 0.13       1.45        1.12 ± 0.34       0.66 ± 0.03
                                                                  
  cAMP\*\*        4.82 ± 0.11       15.13       1.28 ± 0.39       0.59 ± 0.05
                                                                  
  6-MB-cAMP       4.67 ± 0.06       21.38       1.35 ± 0.19       0.81 ± 0.03
                                                                  
  **cCMP\*\***    **4.58 ± 0.14**   **26.30**   **1.84 ± 0.53**   **0.55 ± 0.04**
                                                                  
  **4-MB-cCMP**   **4.05 ± 0.10**   **89.13**   **1.10 ± 0.23**   **0.71 ± 0.06**
                                                                  
  *Sp*-cAMPS      3.72 ± 0.61       190.55      1.38 ± 2.86       0.16 ± 0.01\*
                                                                  
  *Rp*-cAMPS      n.d.              n.d.        n.d.              n.d.
                                                                  
  *Sp*-cCMPS      3.53 ± 0.97       295.12      1.11 ± 1.34       0.17 ± 0.02\*
                                                                  
  *Rp*-cCMPS      n.d.              n.d.        n.d.              n.d.
                                                                  
  cIMP\*\*        4.72 ± 0.04       19.05       1.54 ± 0.16       0.87 ± 0.02
                                                                  
  cUMP\*\*        4.15 ± 0.04       70.79       0.85 ± 0.21       0.72 ± 0.03
                                                                  
  cXMP\*\*        3.98 ± 0.04       104.71      2.06 ± 1.93       0.69 ± 0.03

\*: value shows the maximum activation with 3 mM cNMP without saturation of the concentration/response curve

\*\*: data from Wolter et al, Biochem Biophys Res Commun. 2011, **415**: 563-566.

n.d.: not determinable because of lack of saturation of the concentration/response curve.

cAMP and 6-MB-cAMP showed similar potency, but 6-MB-cAMP had a higher efficacy than cAMP. 4-MB-cCMP was a more effective activator than cCMP, but showed a reduced potency.

The cNMP analogues activated PKGIα in the order of potency cGMP \> 2-MB-cGMP \> cAMP \> 6-MB-cAMP \> cCMP \> 4-MB-cCMP and in the order of efficacy cGMP \> 6-MB-cAMP \> 4-MB-cCMP \> 2-MB-cGMP \> cAMP \> cCMP.

*Rp*-cAMPS and *Rp*-cCMPS did not activate PKGIα. The stable phosphorothioates *Sp*-cAMPS and *Sp*-cCMPS activated PKGIα only at high concentrations in the order of potency and efficacy cGMP \> cAMP \> cCMP \>*Sp*-cAMPS \~ *Sp*-cCMPS.

Furthermore, we illustrate binding of cNMPs for PKG based on existing crystal structures and discuss current problems with respect to molecular modelling approaches. In conclusion, 4-MB-cCMP is a more effective PKG activator than cCMP and, therefore, a valuable tool for analysing the second messenger role of cCMP \[[@B6]\].
